Carla L. Alves

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp et al. · Nature Communications · 2021 · 77 citations · Full text

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer

Carla L. Alves, Daniel Eliáš, Maria Lyng et al. · Clinical Cancer Research · 2016 · 67 citations

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Abeer J. Al-Qasem, Carla L. Alves, Sidse Ehmsen et al. · npj Precision Oncology · 2022 · 67 citations · Full text

Breast Oncology, Chemoprevention Strategy, Cancer Biology +16

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

Carla L. Alves, Daniel Eliáš, Maria Lyng et al. · Breast Cancer Research · 2018 · 43 citations · Full text

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Kamila Kaminska, Nina Akrap, Johan Staaf et al. · Breast Cancer Research · 2021 · 38 citations · Full text